Q-omics provides the consensus-scored BARHL1 profile across patient tissues and cancer cell-line models. BARHL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BARHL1 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, BARHL1 RNA expression shows 8,230 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight MESO, THCA, and LAML as cancer lineages where BARHL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BARHL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BARHL1 survival associations across molecular data types. BARHL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BARHL1 RNA expression–survival associations across cancer types. High BARHL1 expression shows unfavorable associations in MESO, READ, UVM, COAD and UCEC, but favorable associations in BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for BARHL1 RNA expression.
This table summarizes BARHL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BARHL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BARHL1 shows lower tumor expression in THCA and COAD and higher tumor expression in STAD and LIHC. The THCA box plot shows higher BARHL1 RNA expression in normal versus tumor tissue (log2 FC = −0.026, t-test p = .005).
This table shows molecular features associated with BARHL1 in patient tissues and cancer cell lines. In patient samples, BARHL1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, BARHL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
